Ind-Swift Ltd - Stock Valuation and Financial Performance

BSE: 524652 | NSE: INDSWFTLTD | Pharmaceuticals & Drugs | Small Cap

Ind-Swift Share Price

15.20 0.62 4.25%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on Ind-Swift

M-Cap below 100cr DeciZen not available

Ind-Swift stock performance -
15.20 -3.00-17.00% past year

Price Chart, Live Stock Chart, Technical Chart of
P/E Ratio (SA):
1.28
Market Cap:
82.3 Cr.
52-wk low:
13.3
52-wk high:
34.5

Is Ind-Swift Ltd an attractive stock to invest in?

1. Is Ind-Swift Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Ind-Swift Ltd is a average quality company.

2. Is Ind-Swift Ltd undervalued or overvalued?

The key valuation ratios of Ind-Swift Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Ind-Swift Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Ind-Swift Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Ind-Swift:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Ind-Swift Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE %
-10.4%-20.4%-56.2%-10.3%3.4%5.8%7.2%11.7%28.5%26%-
Value Creation
Index
NANANANANANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales
417304263270289330356398411502506
Sales YoY Gr.
--27.1%-13.6%2.6%7.1%14%8.1%11.7%3.3%22.2%-
Adj EPS
-28.8-39.7-33.7-6.5-2.1-5.2-6.1-4.3-3.7-3.111.9
YoY Gr.
-NANANANANANANANANA-
BVPS (₹)
-16.2-53.7-115.4-125.4-124.9-131.7-128.3-133-130.1-127.5-122.6
Adj Net
Profit
-145-200-183-35.1-11.3-28.1-33.1-23.3-20.3-16.764
Cash Flow from Ops.
85.6-1066.71.342.834.683.250.273.115.3-
Debt/CF from Ops.
12.2-9.9156788.623.629.412.320.613.666.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.1%11.7%12.2%22.2%
Adj EPS NANANANA
BVPSNANANANA
Share Price 9.7% 40.3% 7.5% -14.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-421.3143.342.95.41.74.14.73.32.82.4-9.5
Op. Profit
Mgn %
-16.8-51.6-24.92.93.77.111.611.410.210.87.8
Net Profit
Mgn %
-34.8-65.7-69.4-13-3.9-8.5-9.3-5.9-4.9-3.312.7
Debt to
Equity
-15.5-4.1-1.7-1.6-1.5-1.4-1.5-1.4-1.4-1.5-
Working Cap
Days
686799602355317291300281280238120
Cash Conv.
Cycle
391450195-44-89-101-102-67-51-4916

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 12.15%

Return on Equity is Poor

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 9.78%

Latest Financials - Ind-Swift Ltd.

Standalone Consolidated
TTM EPS (₹) 11.9 11.9
TTM Sales (₹ Cr.) 506 506
BVPS (₹.) -122.6 -122.6
Reserves (₹ Cr.) -675 -675
P/BV -0.12 -0.12
PE 1.28 1.28
From the Market
52 Week Low / High (₹) 13.25 / 34.49
All Time Low / High (₹) 1.86 / 88.15
Market Cap (₹ Cr.) 82.3
Equity (₹ Cr.) 10.8
Face Value (₹) 2
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 1.9 -62.82.2 11.82.1 01.9 -14.2
Adj EPS (₹) -0.3 -158-0.1 N/A-0.2 N/A-0.2 N/A
Op. Profit Mgn % -18.56 6992 bps30.73 3124 bps17.22 47 bps12.23 127 bps
Net Profit Mgn % -62.89 -10352 bps-19.27 2329 bps-33.49 622 bps-40.43 -253 bps

Management X-Ray of Ind-Swift:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:55.58%Institutions:0%Non-Institutions:44.42%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%10%20%30%40%50%60%
Pledged *42.8142.8142.8142.8142.8142.8142.8142.810.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Ind-Swift

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Ind-Swift

Adj EPS (Rs.)

Price Chart, Live Stock Chart, Technical Chart of

Sales (Cr.)

Price Chart, Live Stock Chart, Technical Chart of

ROE (%)

Price Chart, Live Stock Chart, Technical Chart of

ROCE (%)

Price Chart, Live Stock Chart, Technical Chart of
Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales417.17304.33263.05269.81289.03329.52356.06397.71410.96502.25
Operating Expenses 487.10461.28328.46263.52278.28306.18314.68352.36368.93453.73
Manufacturing Costs23.4719.4719.9524.0327.4528.4430.1050.8649.0649.53
Material Costs353.43220.48166.03154.16159.95187.73186.52211.02218.04281.18
Employee Cost 39.2736.7738.7944.6746.3348.9351.1757.7563.7572.92
Other Costs 70.93184.56103.6940.6644.5541.0946.8932.7338.0850.11
Operating Profit -69.93-156.95-65.406.3010.7523.3441.3745.3542.0348.51
Operating Profit Margin (%) -16.8%-51.6%-24.9%2.3%3.7%7.1%11.6%11.4%10.2%9.7%
Other Income 1.8712.5113.6814.578.4422.3815.2223.5511.8557.99
Interest 39.9318.9716.3211.463.7735.1952.1857.1659.7662.94
Depreciation 39.3636.3535.7334.6333.9733.5932.7032.0728.6727.11
Exceptional Items 00-259.61-28.1526.746.40-1.210.7360.580
Profit Before Tax -147.36-199.77-363.37-53.388.19-16.66-29.49-19.6026.0416.46
Tax -2.230.170.890.7502.460.320.4202.23
Profit After Tax -145.13-199.94-364.27-54.138.19-19.12-29.82-20.0226.0414.23
PAT Margin (%) -34.8%-65.7%-138.0%-20.1%2.8%-5.8%-8.4%-5.0%6.3%2.8%
Adjusted EPS (₹)-28.8-39.7-67.3-10.01.5-3.5-5.5-3.74.82.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund -46.18-246.16-611.01-679.37-676.74-713.12-695.16-720.32-704.70-690.83
Share Capital 24.2724.2725.0310.8310.8310.8310.8310.8310.8310.83
Reserves -70.45-270.43-636.04-690.20-687.57-723.95-706-731.15-715.53-701.66
Minority Interest0000000000
Debt910.431,042.911,048.291,055.241,008.551,014.771,020.03984.81757.971,013.86
Long Term Debt541.41671.65664.77681.20644.67644.21644.17619.30403.111,009.50
Short Term Debt369.02371.25383.52374.04363.88370.56375.86365.51354.864.36
Trade Payables150.26175.38161.76180.12198.83226.22232.02203.91234.73201.89
Others Liabilities 213.3288.6670.0156.7767.7873.77114.69163.36361.21129.55
Total Liabilities 1,227.831,060.78669.06612.77598.42601.65671.57631.76649.21654.47

Fixed Assets

Gross Block565.68572.52576.38576.33589.92601.49607.40630.13637.40552.63
Accumulated Depreciation162.02198.37234.07265.65299.37331.83363.39394.63420.94368.58
Net Fixed Assets403.66374.14342.31310.68290.56269.66244.01235.50216.46184.05
CWIP 3.893.672.2200013.06929.7351.24
Investments 45.1245.1243.9043.9141.2624.0670.3164.3553.731.26
Inventories113.3790.9439.0645.444952.4162.8569.5889.3564.09
Trade Receivables485.48380.33108.4883.5075.5694.17107.9590.62104.58152.14
Cash Equivalents 16.9817.399.113.6819.7216.7628.9916.1813.3363.14
Others Assets159.33149.19123.98125.56122.33144.59144.41146.51142.03138.55
Total Assets 1,227.831,060.78669.06612.77598.42601.65671.57631.76649.21654.47

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 85.57-105.796.721.3442.7934.6083.1950.2073.0515.28
PBT -147.36-199.77-363.37-53.388.19-19.12-28.29-20.34-34.5416.46
Adjustment 90.75168.51321.1573.1221.3252.6888.1277.9485.2345.92
Changes in Working Capital 142.19-74.5448.95-18.4113.271.0323.68-6.9822.36-47.1
Tax Paid 000000-0.32-0.4200
Cash Flow From Investing Activity -5.52-4.01-4.30-2.73-13.71-11.35-16.71-18.42-29.3576.61
Capex -5.73-4.18-4.45-2.86-13.99-12.37-20.13-19.48-30.12-21.28
Net Investments 0.01000001.600095.95
Others 0.200.170.150.140.281.011.811.060.771.94
Cash Flow From Financing Activity -80.97110.21-10.71-4.04-13.03-26.20-54.25-44.60-46.56-42.08
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000-74.19-207.89-118.72
Interest Paid -37.49-21.68-15.26-1.15-3.59-32.73-52.92-58.27-63.69-63.43
Dividend Paid 0000000000
Others -43.48131.894.56-2.90-9.446.53-1.3387.87225.03140.07
Net Cash Flow -0.910.41-8.28-5.4316.05-2.9612.23-12.81-2.8549.81
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0.320.270.310.420.480.560.580.620.650.81
PAT to CFO Conversion(x)N/AN/AN/AN/A5.22N/AN/AN/A2.811.07
Working Capital Days
Receivable Days40051333412910092100908589
Inventory Days1591218957605557606953
Payable Days176270371405432413448377367283

Ind-Swift Ltd Stock News

Ind-Swift Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Ind-Swift on 21-Feb-2025 16:59 is ₹15.20.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of Ind-Swift stood at ₹82.33.
The latest P/E ratio of Ind-Swift as of 21-Feb-2025 16:59 is 1.28.
The latest P/B ratio of Ind-Swift as of 21-Feb-2025 16:59 is -0.12.
The 52-week high of Ind-Swift is ₹34.49 and the 52-week low is ₹13.25.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ind-Swift is ₹505.6 ( Cr.) .

About Ind-Swift Ltd

Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

  • A well accepted expertise in NDDS, in India and the world over.
  • A US patent for Clarie OD, with a market size of $300 million.
  • Another patent for Fexofenadine ODT with a market size of $2.5 billion.
  • Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Awards/ Achievements

  • Ranked as one of the most promising pharmaceutical group in India by Express Pharma Pulse.
  • All India achievers award as legend in Business house category.
  • An ISO 9001, 2000 company.
  • Achieved Pharma Pulse award as fastest growing & most promising pharmaceutical company for three successive years.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on